TO THE EDITOR:
Lindson-Hawley and colleagues (1) report a randomized trial comparing 2 smoking cessation strategies using NRT (1) . The abrupt-cessation strategy led to higher quit rates than the gradual-cessation strategy at 1 and 6 months.
However, when looking at the details, one realizes that "abrupt cessation" is not what one generally would expect: Complete cessation on the target quit date and immediate initiation of NRT, as generally recommended in the package inserts of such therapy. This was not done. The abrupt strategy in this trial was less "abrupt" and more prepared than it may seem because it included precessation NRT (use of a nicotine patch for 2 weeks before the quit date while participants continued to smoke) and participants were given the task to identify "the times of the day when cigarettes would be the hardest to give up and [plan] strategies to avoid relapse after the quit day" in this 2-week phase (1) . After the target quit date, both treatment groups received the same NRT.
This strategy is not (yet) a standard procedure and not (yet) widely recommended in guidelines. It is not generally called abrupt cessation but rather pretreatment with NRT or precessation NRT and has been studied for more than a decade (2) .
Gradual cessation is a concept where by smoking is generally faded out over 2 to 3 weeks, aiming for complete cessation within this time frame. "Gradual" may be perceived by smokers as a lengthy process where by cigarette consumption is slowly reduced. In the gradual-cessation group, an NRT patch was used 2 weeks before the quit date and additional use of short-acting NRT was recommended but largely underused. Of note, gradual reduction appealed to many smokers and was associated with failure to quit smoking. Underdosing of short-acting NRT is common and may be related to its instructions for use. In my experience, informing patients about the maximum daily dose permitted and encouraging them to initially consume at least one half of that dose increases use and success.
Although Lindson-Hawley and colleagues' study was welldesigned and well-performed, the terminology used to describe the successful strategy was misleading: Even reputable organizations noted that the abrupt strategy included 2 weeks of a precessation nicotine patch (3) . This misleading terminology poses a missed opportunity to communicate the simple details of the successful strategy in this trial. This shortcoming is likely to jeopardize the translation of this study's relevant findings into clinical practice. Metabolically Healthy Obesity and Development of Chronic Kidney Disease TO THE EDITOR: Chang and colleagues (1) report that overweight and obesity are associated with an increased incidence of chronic kidney disease (CKD) in metabolically healthy young and middle-aged adults. As global obesity rates continue to climb (2) , evaluating the substantial role that obesity plays in the development of such comorbidities as CKD is important. Obesity is a complex, multifactorial chronic disease, and the authors should consider several points before we are able to extrapolate their results and their potential effect on the greater population of persons with obesity.
Previous studies have shown that persons who are overweight (body mass index [BMI], 25.0 to 29.9 kg/m 2 ) or have class 1 (BMI, 30.0 to 34.9 kg/m 2 ) or class 2 (BMI, 35.0 to 39.9 kg/m 2 ) obesity have a lower risk for cardiovascular-and cancer-related deaths and deaths not related to these factors (3). The authors should consider the "obesity paradox" in patients with CKD. Although obesity is often associated with poor outcomes in many comorbid conditions, several studies show that it is related to improved survival in CKD (4). In addition, although previous studies have shown that the incidence of CKD increases in persons with obesity regardless of whether they have coexisting metabolic syndrome, whether CKD portends greater morbidity in this population is unclear (5).
The authors also suggest a linear relationship between BMI and CKD in their metabolically healthy cohort, but one must recognize that obesity is a heterogeneous chronic disease that clearly presents in many different phenotypes. Few clearly understood factors account for the differences in patients with obesity and the risk for CKD. In addition, although the authors did account for ethnicity by including Asianspecific cutoffs for BMI, the BMI of the homogeneous cohort ranged up to only 35.0 kg/m 2 , which excludes persons with more severe forms of obesity. The higher BMI category in this study included those with a BMI greater than 25.0 kg/m 2 , which primarily consisted of older men who may have had higher all-cause morbidity. We would have liked the authors to include data at higher BMI categories.
In their longitudinal study of metabolically healthy workers, Chang and colleagues (1) showed that higher BMI categories were associated with an increased incidence of CKD. They interpreted this finding as an adverse consequence of adiposity. However, their description of participant subgroups suggests that the association reported between elevated BMI and incident CKD was driven by relationships found primarily among older adults, men, and persons who exercise frequently. These are subgroups in which BMI status might reflect variations in the preservation or formation of muscle mass rather than the accumulation of adipose tissue. Greater muscle mass leads to increased production of creatinine, which in turn is associated with a reduced estimated glomerular filtration rate (GFR) (2) consistent with the final row of Our curiosity leads to testable hypotheses. We suggest that Chang and colleagues use their Kangbuk Samsung Health Study to assess whether the decline in the estimated GFR might be associated more strongly with baseline lean mass rather than adipose tissue. As the authors recently reported (3), their healthy-worker cohort also provided measurements of bioelectric impedance and waist circumference. Thus, baseline values can be calculated for the percentage of fat and fat-free mass and the waist-height ratio.
Controversies exist about how to interpret BMI (4, 5) . To clarify how it contributes to the decline in the estimated GFR, the authors could consider which tissue components or anatomical distributions of body mass best predict the described outcome. The absence of data on albuminuria is a major weakness of this analysis and precludes a basic assessment of the participants' CKD status and risk for adverse health outcomes, such as cardiovascular mortality and end-stage renal disease (2) . Serum creatinine concentrations correlate significantly with body weight, so a decreased estimated GFR in obese participants may have resulted from elevated serum creatinine levels due to increased creatinine production rather than decreased GFR (3). Serum cystatin C levels do not correlate with body weight (3). Estimation of the GFR using both serum creatinine and serum cystatin C levels (GFRcr-cys) improves the accuracy and precision of the estimated GFR and decreases false-positive CKD diagnoses (4). In 1 study, 38% of participants with an estimated GFR obtained by using serum creatinine levels between 45 and 59 mL/min/1.73 m 2 had a measured GFR of 60 mL/min/1.73 m 2 or greater (4). In 44% of these participants, estimation of the GFRcr-cys enabled appropriate reclassification to an estimated GFR of 60 mL/min/ 1.73 m 2 or greater (4). We recently reported our experience implementing CKD guidelines suggesting estimation of the GFRcr-cys for participants with an estimated GFR obtained by using serum creatinine levels between 45 and 59 mL/min/1.73 m 2 and no other markers of kidney damage (5). The estimated GFRcr-cys was higher than that obtained using serum creatinine levels in all 50 participants and was 60 mL/min/1.73 m 2 or greater in 88% of participants. Rates of overweight and obesity were 32% and 56%, respectively, suggesting confounding of the estimated GFR obtained by using serum creatinine levels due to increased body weight.
In summary, we contend that conclusions about metabolically healthy obesity and CKD cannot be made without further study using albuminuria and the estimated GFRcr-cys. 
IN RESPONSE:
We thank Drs. Stanford and Butsch, Drs. Kahn and Pavkov, and Dr. Little and colleagues for their interest in our study and for raising important points about the interpretation of our results. Several of the arguments address the use of Asian-specific cutoffs for BMI and the obesity paradox. For a given BMI, Asians have a higher percentage of total body fat (1) and a higher risk for cardiometabolic disease (2) than white persons. As a consequence, Asian Pacific-specific BMI criteria have gained widespread acceptance. As for more detailed analyses by degree of obesity, only 211 (0.3%) participants in our study had higher-grade obesity (BMI ≥ 30 kg/m 2 ) and we could not perform a separate analysis of this subgroup. The obesity paradox refers to the inverse association between obesity and mortality commonly found in participants older than 50 years or those with established cardiovascular disease or other comorbidities (3) (4) (5) . It has raised concerns about selection, survival, treatment, and confounding biases (4, 6, 7). Our cohort comprised relatively young, metabolically healthy, asymptomatic Korean men and women, and our findings are less likely to be affected by survival biases or biases induced by comorbidities or treatment than studies in higherrisk populations. Furthermore, our findings are consistent with an extensive body of evidence indicating that BMI is linearly associated with the development of metabolic abnormalities, such as insulin resistance, type 2 diabetes, and hypertension (4, 8)-all risk factors for CKD.
Body mass index is an imperfect surrogate for adiposity, and we agree that body composition and fat distribution are important to understand the association between BMI and incident CKD. One of the study centers unfortunately did not measure waist circumference until 2012, and we could not evaluate the effect of fat distribution on CKD outcomes. With respect to body composition, the correlation of BMI with fat mass and with lean mass measured by an impedance analyzer (InBody 3.0 and 720 [Biospace]) was 0.87 and 0.50, respectively, in women and 0.87 and 0.59, respectively, in men. The correlation between fat mass and lean mass was 0.34 in women and 0.41 in men. When fat mass and lean mass were simultaneously included in survival models adjusted for age, study center, year of screening examination, smoking status, alcohol intake, and physical activity, the adjusted 5-year risk differences for incident CKD comparing quartiles 2 to 4 of fat mass with quartile 1 were Ϫ3.3 (95% CI, Ϫ8.8 to 2.2), Ϫ3.4 (CI, Ϫ8.7 to 2.0), and Ϫ6.1 (CI, Ϫ11.2 to Ϫ1.1) cases per 1000 women, respectively, and Ϫ0.5 (CI, Ϫ4.9 to 4.0), Ϫ0.7 (CI, Ϫ5.1 to 3.6), and Ϫ3.2 (CI, Ϫ7.4 to 1.1) cases per 1000 men, respectively. The corresponding risk differences for lean mass were 4.6 (CI, 1.2 to 8.0), 9.2 (CI, 5.5 to 12.8), and 14.0 (CI, 9.7 to 18.4) cases per 1000 women, respectively, and 4.4 (CI, 1.8 to 6.9), 7.9 (CI, 4.8 to 11.0), and 13.6 (CI, 9.0 to 18.2) cases per 1000 men, respectively. In these analyses, lean mass was thus associated with increased risk for CKD, whereas fat mass was not.
The implications of these results for the interpretation of the association between BMI and CKD are unclear, because increased BMI is associated with increases in both fat and lean mass. However, these findings highlight the limitations of creatinine-based indices to assess kidney function as well as the need to evaluate the association between obesity and CKD using biomarkers that do not depend on muscle mass. Climate Change and Health TO THE EDITOR: I read with dismay Crowley's position paper calling for "urgent action" on climate change (1). With egregious overreach, the American College of Physicians (ACP) abandoned its expertise in medicine to preach about atmospheric science. This should strike physicians with the same incredulity that we would feel if the National Oceanic and Atmospheric Administration were to issue a policy on best practices for managing diabetes. This ACP position paper tarnishes the College's distinguished reputation by seeming to promote a biased political agenda.
As soon as I read "ninety-seven percent of climate scientists agree that humans are largely causing global warming," I knew that Crowley was influenced by sensationalism over science. His "97%" canard is attributable to Cook and colleagues (2), and Crowley should know that this statistic has been discredited (3). Cook and colleagues reviewed 12 000 relevant abstracts but found that only 34% even expressed an opinion about manmade climate change, whereas 33% seemed to support it. He divided 33 by 34 to get 97%. If the Annals received a research submission with such shoddy methodology, it would be summarily rejected.
If the authors seek consensus, consider Lindzen's assertions of points of agreement between skeptical and alarmist atmospheric scientists (www.prageru.com/courses /environmental-science/climate-change-what-do-scientists -say):
1) The climate is always changing. 2) CO2 is a greenhouse gas without which life on earth is not possible, but adding it to the atmosphere should lead to some warming. Crowley demands "urgent action" with reckless disregard for the consequential cost, the negligible reward (4), the prospect that warming actually has some benefits (5), and any evidence contrary to his conclusions (www.mediatheque .lindau-nobel.org/videos/34729/ivar-giaever-global-warming -revisited/laureate-giaever), not to mention Ockham's razor and the null hypothesis. Thus, he abandons our vital adage to first, do no harm.
As a physician, I turn to the ACP for insight on the practice of medicine. Please do not strain the credibility of this organization by advocating policy that is politically biased and outside its area of expertise. TO THE EDITOR: In a position paper on climate and health, Crowley recommends that physicians "advocate for climate change adaptation and mitigation policies" (1) . As an internist and infectious disease specialist, I find this recommendation difficult to follow. Such advocacy might also compromise my ability to influence patients in other areas of health care.
As a physician, it is my responsibility to analyze data provided in the medical literature and not just blindly accept conclusions that are stated even by prestigious medical societies. My education and training allow me to review medical data and come to conclusions about their reliability and importance. However, I do not possess the tools to analyze data from scientific areas outside of medicine, such as climate change, to form opinions. I respect the integrity and knowledge of the Intergovernmental Panel on Climate Change, which states that "human influence on the climate system is clear." However, without my own understanding of the science, I am uncomfortable advocating for the policies that Crowley recommends, especially when I might be challenged by persons with more educational background in this area.
As a physician, I am often confronted with patients' opinions that are contrary to the medical literature. Some examples include vaccine hesitancy, insistence on antibiotics to "knock out a cold," demand for long-term antibiotics for "chronic Lyme disease," and reluctance to use statins when indicated. In these areas, I can confidently present my position to patients, often succeeding in convincing them to reevaluate their positions. Fighting for climate change adaptation and mitigation policies is a position I can defend only on the basis of belief in the recommendations made by others and not through independent analysis of data. Doing so may compromise my ability to convince patients in areas where I do have the background and training to understand and present the data. Patients may interpret my advocacy in areas in which I have limited knowledge as an indication of biased recommendations not based on facts.
Understanding the effects of climate change on human and environmental health is important for patient management. This knowledge is based on medical data that I can interpret independently. Advocating for climate change adaptation and mitigation without understanding the facts is challenging and may compromise my ability to properly care for patients. 
Daniel S. Berman, MD

TO THE EDITOR:
The burning of fossil fuel is not the only cause of climate change, as noted in Crowley's introductory statement (1) . However, the declaration that "deforestation . . . [and] agriculture and food production . . . all release carbon dioxide and other greenhouse gases" omits an important distinction. Although the production of food is necessary for human life, raising food animals-especially beef cattlecontributes to deforestation and greenhouse gas emissions far more than growing plants for human consumption (2) . Moreover, the Scientific Report of the 2015 Dietary Guidelines Advisory Committee (3) recommends that persons in the United States reduce their intake of beef and other animal products for 2 reasons: Such a diet is healthier than the current standard diet in the United States, and continuing animal production at current rates is unsustainable and harmful to the environment. This advice was removed from the final guidelines (4) for political reasons (5). The ACP should include a statement in their position paper on climate change and health urging physicians to advise a diet lower in animal products and higher in whole-plant products to improve the health of both their patients and their environment. 
IN RESPONSE:
We respectfully disagree with Dr. Mondrow's claim that ACP's policy paper on climate change and health is an "egregious overreach" that is outside the College's mission. The ACP became involved in analyzing the health effects of climate change and developing our policy paper at the request of our Board of Governors-leaders of our state and international chapters elected by the membership. The Board of Governors' resolution asked the Board of Regents to support efforts to educate and respond to the medical consequences of climate change affecting or potentially affecting patients. The Board of Regents adopted the resolution in November 2014.
As requested by the Board of Governors, our Health and Public Policy Committee-made up of practicing internistmembers-reviewed the evidence on climate change's effect on human health and concluded that it poses an immediate and longer-term threat to individual and population health. The committee's draft position paper was reviewed and commented upon by our Board of Governors; ACP's councils of student members, young physicians, residents, and subspecialties; and independent experts in the science of climate change and its effect on health before being adopted as policy by ACP's Board of Regents. This process, involving review of the draft by hundreds of ACP members, ensured that the full and diverse range of views within our membership was considered.
As atmospheric science does not fall within ACP's usual purview, it relied on the work of trusted, objective expertsincluding the National Academy of Sciences and the Royal College, the National Aeronautics and Space Administration, and the Intergovernmental Panel on Climate Change-to reach its conclusion that the warming of climate is definite and that climate change is largely caused by human activity. These organizations do have the expertise to review the relevant data, and their consensus on anthropogenic climate change is clear.
Dr. Mondrow's claim that the statement that "ninetyseven percent of climate scientists agree that humans are largely causing global warming" has been discredited is also unfounded. Although some proponents of doing nothing to address climate change have questioned the accuracy of Cook and colleagues' study, it was recently bolstered in the peer-reviewed scientific journal Environmental Research Letters in which the authors concluded that "the consensus that humans are causing recent global warming is shared by 90%-100% of publishing climate scientists according to six independent studies by co-authors of this paper" and "the finding of 97% consensus in published climate research is robust and consistent with other surveys of climate scientists and peerreviewed studies" (1) .
We believe that the paper on climate change and health objectively describes how climate change has affected, is affecting, and will continue to affect human health, from exacerbating respiratory disease to increasing the risk for heatrelated illness. Climate change is an individual and public health issue. Because it affects the patients whom our members treat, ACP believes that it is imperative that our members work to become educated about climate change and health, reduce the greenhouse gas footprint of their own practices, and advocate for policies to adapt to and mitigate climate change.
Dr. Berman expresses concern about Recommendation 3 of the position paper, which states, "Physicians, both individually and collectively, are encouraged to advocate for climate change adaptation and mitigation policies and communicate about the health cobenefits of addressing climate change in objective, simple language to their community and policymakers." He proposes that physicians may lack the expertise to independently analyze climate change research, making it difficult to effectively discuss climate change adaptation and mitigation policies with their patients. We clarify that the intent of the recommendation is to call on physicians and other health care professionals, both individually and collectively, to advocate for action to address climate change to members of their community and policymakers.
To assist our members in this charge, ACP has developed a Climate Change Action Plan, a toolkit including talking points and presentation slides that can be used for chapter presentations, grand rounds, and other educational opportunities. Because health care-and particularly hospitals-is among the most energy-intensive commercial sectors, the toolkit includes a collection of "Greening the Health Care Sector" documents to help guide physicians and their colleagues to make their practices and facilities more environmentally sustainable by addressing energy management, transportation, waste and food, and the built environment. The toolkit includes a Patient FACTS education document developed by ACP's Center for Patient Partnership in Healthcare, part of the College's patient-tested educational series designed to help patients increase their understanding of health issues.
We agree with Dr. Reines that agriculture and food production are major sources of greenhouse gas emissions and that reducing meat protein consumption could help mitigate climate change. According to the Intergovernmental Panel on Climate Change, the agriculture, forestry, and other land use sector is responsible for approximately 25% of anthropogenic greenhouse gas emissions (2) . Under the rationale for Position 1, which recommends the development and implementation of strategies to adapt to and mitigate climate change, ACP's policy paper states, "The agricultural sector is a major source of global greenhouse gas emissions, such as methane from livestock. By reducing demand for greenhouse gas-intensive meat in high-income countries and shifting to healthier diets rich in legumes, fruits, and vegetables, environmental and health cobenefits could be realized." The aforementioned ACP Climate Change Action Plan includes a document summarizing how the health care sector can reduce its greenhouse gas footprint by eliminating waste and encouraging consumption of healthy, local foods. (1) . This proposal might facilitate independent verification of trial results, improve reliability of meta-analyses (2), and enable generation of new hypotheses based on subgroup and secondary outcome analyses. However, releasing individual-patient data also increases the risk for patient identification by third parties, particularly for patients with rare conditions or for data sets that include genetic information (3, 4) . Little is known about patient attitudes or how this new policy might affect study enrollment.
Objective: To measure patient attitudes toward sharing deidentified individual-patient data from clinical trials.
Methods: We collected data in a single U.S. emergency department between January and April 2015. Patients were eligible if they spoke English, were at least 18 years of age, had normal mental status, and had an Emergency Severity Index score between 2 and 5 (no critical needs).
Research assistants approached eligible patients during randomly selected 2-hour blocks between 9:00 a.m. and 10:00 p.m., 7 days per week. The assistants briefly explained deidentified individual-patient data and used examples to describe the potential risks and societal benefits of data sharing. They then asked patients about their attitudes toward sharing these data.
Findings: Of 1691 eligible patients, 799 (47%) agreed to participate. Participants had a median age of 50 years (interquartile range, 37 to 62 years), and 59% were women. Fiftyone percent were white, 32% were black, and 16% were Hispanic. Forty-eight percent received education beyond high school. Sixteen percent had previously participated in clinical research. Fifty-eight percent favored or strongly favored data sharing, and only 9% were against or strongly against it (Table). Most reported that data sharing would either increase (34%) or not affect (41%) their participation in a clinical trial, but 25% indicated that they would be less likely to participate. Most participants (84%) also believed that disclosing the datasharing plan during the informed consent process was important or very important. Responses did not differ by age or sex, but a higher percentage of minority participants was against data sharing (white, 6%, vs. other, 13%; P < 0.001) and would be less likely to participate in a study if deidentified data were made public (white, 18%, vs. other, 32%; P < 0.001). 25  35  45  55  65  75  85 Age, y fection (5). We believe that the main drivers of this success are the continuous advent of new drug classes, better management of comorbidity, stronger focus on lifestyle-related risk factors, and more effective HIV detection leading to earlier presentation for care. Despite these advances, many persons with HIV infection globally lack access to care and treatment and many others are not reaping the possible benefits even when they do have access. We should address these limitations because this report and others like it document the benefits we can expect with a strong focus on timely diagnosis, integrated solutions, and new therapies. 
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